CA2941870C - Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use - Google Patents
Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use Download PDFInfo
- Publication number
- CA2941870C CA2941870C CA2941870A CA2941870A CA2941870C CA 2941870 C CA2941870 C CA 2941870C CA 2941870 A CA2941870 A CA 2941870A CA 2941870 A CA2941870 A CA 2941870A CA 2941870 C CA2941870 C CA 2941870C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- aak1
- disease
- mice
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461953976P | 2014-03-17 | 2014-03-17 | |
| US61/953,976 | 2014-03-17 | ||
| PCT/US2015/020696 WO2015142714A1 (en) | 2014-03-17 | 2015-03-16 | Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2941870A1 CA2941870A1 (en) | 2015-09-24 |
| CA2941870C true CA2941870C (en) | 2022-07-19 |
Family
ID=52727478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2941870A Active CA2941870C (en) | 2014-03-17 | 2015-03-16 | Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9682982B2 (https=) |
| EP (2) | EP3719021B1 (https=) |
| JP (1) | JP6553081B2 (https=) |
| CN (1) | CN106103447B (https=) |
| AR (1) | AR099766A1 (https=) |
| AU (1) | AU2015231672B2 (https=) |
| CA (1) | CA2941870C (https=) |
| DK (2) | DK3719021T3 (https=) |
| ES (2) | ES2821441T3 (https=) |
| HU (1) | HUE050975T2 (https=) |
| PL (2) | PL3719021T3 (https=) |
| PT (2) | PT3719021T (https=) |
| TW (1) | TW201620911A (https=) |
| WO (1) | WO2015142714A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2834243B1 (en) * | 2012-03-09 | 2018-04-25 | Lexicon Pharmaceuticals, Inc. | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
| WO2015054358A1 (en) | 2013-10-11 | 2015-04-16 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CN109369576B (zh) * | 2018-09-19 | 2020-11-27 | 上海凌凯医药科技有限公司 | 一种合成3-甲基氧杂环丁烷-3-(4-硝基苯基)碳酸酯的方法 |
| AU2021259419A1 (en) | 2020-04-21 | 2022-11-10 | Lexicon Pharmaceuticals, Inc. | AAK1 inhibitors for use in treating viral infections |
| US11666575B2 (en) | 2020-04-21 | 2023-06-06 | Lexicon Pharmaceuticals, Inc. | Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections |
| WO2023196584A2 (en) * | 2022-04-08 | 2023-10-12 | New York University | Endocytosis inhibitors and their use for pain treatment |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US6194410B1 (en) * | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
| EP1873157A1 (en) * | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| US8591943B2 (en) * | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| WO2011030139A1 (en) * | 2009-09-11 | 2011-03-17 | Astrazeneca Ab | 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators |
| US8946237B2 (en) * | 2010-01-14 | 2015-02-03 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-A]pyrimidines as mark inhibitors |
| WO2012034095A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| DK2822555T3 (en) * | 2012-03-09 | 2018-02-05 | Lexicon Pharmaceuticals Inc | Inhibition of adapter-associated kinase 1 for the treatment of pain |
| RU2014140739A (ru) * | 2012-03-09 | 2016-04-27 | Лексикон Фармасьютикалз, Инк. | Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения |
| EP2834243B1 (en) | 2012-03-09 | 2018-04-25 | Lexicon Pharmaceuticals, Inc. | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
-
2015
- 2015-03-04 TW TW104106872A patent/TW201620911A/zh unknown
- 2015-03-16 US US14/658,653 patent/US9682982B2/en active Active
- 2015-03-16 PL PL20177604T patent/PL3719021T3/pl unknown
- 2015-03-16 EP EP20177604.4A patent/EP3719021B1/en active Active
- 2015-03-16 DK DK20177604.4T patent/DK3719021T3/da active
- 2015-03-16 CA CA2941870A patent/CA2941870C/en active Active
- 2015-03-16 PT PT201776044T patent/PT3719021T/pt unknown
- 2015-03-16 CN CN201580014255.6A patent/CN106103447B/zh active Active
- 2015-03-16 PT PT157120262T patent/PT3119783T/pt unknown
- 2015-03-16 ES ES15712026T patent/ES2821441T3/es active Active
- 2015-03-16 DK DK15712026.2T patent/DK3119783T3/da active
- 2015-03-16 HU HUE15712026A patent/HUE050975T2/hu unknown
- 2015-03-16 WO PCT/US2015/020696 patent/WO2015142714A1/en not_active Ceased
- 2015-03-16 JP JP2016557251A patent/JP6553081B2/ja active Active
- 2015-03-16 EP EP15712026.2A patent/EP3119783B1/en active Active
- 2015-03-16 ES ES20177604T patent/ES2911388T3/es active Active
- 2015-03-16 AU AU2015231672A patent/AU2015231672B2/en active Active
- 2015-03-16 PL PL15712026T patent/PL3119783T3/pl unknown
- 2015-03-16 AR ARP150100787A patent/AR099766A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015231672A1 (en) | 2016-09-15 |
| CN106103447B (zh) | 2019-07-16 |
| HK1226065A1 (zh) | 2017-09-22 |
| WO2015142714A1 (en) | 2015-09-24 |
| EP3719021A1 (en) | 2020-10-07 |
| PL3119783T3 (pl) | 2021-01-11 |
| EP3119783B1 (en) | 2020-06-24 |
| TW201620911A (zh) | 2016-06-16 |
| PL3719021T3 (pl) | 2022-06-20 |
| ES2911388T3 (es) | 2022-05-19 |
| US20160039824A1 (en) | 2016-02-11 |
| CA2941870A1 (en) | 2015-09-24 |
| AU2015231672B2 (en) | 2019-06-20 |
| CN106103447A (zh) | 2016-11-09 |
| HUE050975T2 (hu) | 2021-01-28 |
| PT3119783T (pt) | 2020-09-24 |
| EP3719021B1 (en) | 2022-03-09 |
| US9682982B2 (en) | 2017-06-20 |
| DK3119783T3 (da) | 2020-09-28 |
| DK3719021T3 (da) | 2022-06-13 |
| PT3719021T (pt) | 2022-04-08 |
| AR099766A1 (es) | 2016-08-17 |
| JP2017507980A (ja) | 2017-03-23 |
| EP3119783A1 (en) | 2017-01-25 |
| ES2821441T3 (es) | 2021-04-26 |
| JP6553081B2 (ja) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2941870C (en) | Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use | |
| KR101965025B1 (ko) | 피라졸로[1,5-a]피리미딘계 화합물, 그를 포함하는 조성물 및 그의 사용 방법 | |
| CA2923317C (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| EP2822952B1 (en) | Aryl ether-base kinase inhibitors | |
| CA2923420A1 (en) | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use | |
| HK1226065B (zh) | 连接物关联激酶1的抑制剂、包含其的组合物、及其使用方法 | |
| WO2025068452A1 (en) | Guanfacine derivatives and their use in treating cancer | |
| WO2025068461A1 (en) | Guanfacine derivatives and their use in treating cancer | |
| HK1217658B (zh) | 基於吡唑并[1，5-a]嘧啶的化合物、包含其的组合物和其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200302 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241218 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241219 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241219 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260203 |